摘要
鼻咽癌(NPC)是一类具有地域性、民族性和种族分布的癌症。某些遗传、种族和环境因素与鼻咽癌的发病机制有关和,更重要的是,在大多数病人中发现有EB病毒(EBV)的存在。由于没有特异性的症状,NPC病人只有在晚期才能得到诊断,因此,其治疗效果不佳。目前,由于化疗和放疗的低生存率、严重的并发症、肿瘤转移和复发等原因,治疗该癌症需要制定更好的治疗方案。最近的研究表明,表观遗传机制如DNA甲基化、组蛋白修饰和小分子RNA在EBV基因组以及在宿主细胞会发生改变,这可能发生在鼻咽癌的发生和发展之前。组蛋白乙酰转移酶(HATs)和组蛋白去乙酰化酶(HDAC)介导的组蛋白乙酰化和去乙酰化能调节基因表达和某些细胞学过程。HDACs还参与维持EBV的潜伏周期,因此,HDAC抑制剂(HDACi)是EBV激活的有效诱导剂,这对裂解蛋白的表达十分关键,当在单独使用或添加其他抗肿瘤药物治疗EBV相关的恶性肿瘤,这可以提供新的治疗靶点以及介导增强癌细胞的杀死率。最近,FDA批准的三种HDACi已用于临床治疗T细胞淋巴瘤,而其他一些药物则在临床试验中,这使组蛋白修饰成为靶向治疗的较好选择。本文总结了NPC表观遗传机制改变,并侧重介绍了用于靶向治疗的组蛋白修饰。
关键词: 表观遗传学,DNA甲基化,组蛋白去乙酰化酶抑制剂、组蛋白修饰、microRNA分子治疗,鼻咽癌。
Current Medicinal Chemistry
Title:Histone Modifications as Molecular Targets in Nasopharyngeal Cancer
Volume: 23 Issue: 2
Author(s): Sukanya Shyamasundar, S. Thameem Dheen and B. Huat Bay
Affiliation:
关键词: 表观遗传学,DNA甲基化,组蛋白去乙酰化酶抑制剂、组蛋白修饰、microRNA分子治疗,鼻咽癌。
摘要: Nasopharyngeal carcinoma (NPC) is a cancer of the nasopharyngeal epithelium with distinct geographical, ethnic and racial distribution. Several genetic, ethnic and environmental risk factors, have been implicated in nasopharyngeal pathogenesis and of significance, is the Epstein - Barr virus (EBV)- latent infection observed in most patients. Patients with NPC are typically diagnosed only in advanced stages due to non-specific symptoms, and hence, they respond poorly to therapy. Currently, low survival rates, severe complications, tumour metastasis and recurrence following chemo-radiotherapy, delineate the need for better therapeutic options to combat the disease. Recent studies have shown that epigenetic mechanisms such as DNA methylation, histone modifications and microRNAs, which are altered in the EBV genome as well as in the host cells, may underlie the initiation and progression of NPC. Histone acetylation and deacetylation which are mediated by enzymes, namely histone acetyl transferases (HATs) and histone deacetylases (HDACs), are known to regulate gene expression and several cellular processes. HDACs are also involved in maintaining the EBV latent cycle and thus, HDAC inhibitors (HDACi) are potent inducers of EBV reactivation, which is critical for the expression of the lytic proteins, thereby providing novel targets for therapy, as well as mediating enhanced killing of cancer cells, when used alone or along with additional anti-cancer agents in EBV associated malignancies. Recently, three FDA- approved HDACi have been used for the treatment of T-cell lymphoma, while several others are in clinical trials, making histone modifications excellent candidates for targeted therapy. In this review, we summarize the epigenetic mechanisms altered in NPC, with a focus on histone modifications for targeted therapy.
Export Options
About this article
Cite this article as:
Sukanya Shyamasundar, S. Thameem Dheen and B. Huat Bay , Histone Modifications as Molecular Targets in Nasopharyngeal Cancer, Current Medicinal Chemistry 2016; 23 (2) . https://dx.doi.org/10.2174/0929867323666151106125631
DOI https://dx.doi.org/10.2174/0929867323666151106125631 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Specific Targeting of Akt Kinase Isoforms: Taking the Precise Path for Prevention and Treatment of Cancer
Current Drug Targets Predictive Factors of Febrile Neutropenia Induced by Anticancer Chemotherapy in the South of Tunisia
Reviews on Recent Clinical Trials Editorial (Personalized Medicine in the Age of Pharmacoproteomics: A Close up on India and Need for Social Science Engagement for Responsible Innovation in Post-Proteomic Biology)
Current Pharmacogenomics and Personalized Medicine Nanomedicine to Deal With Cancer Cell Biology in Multi-Drug Resistance
Mini-Reviews in Medicinal Chemistry Current Progresses in Metal-based Anticancer Complexes as Mammalian TrxR Inhibitors
Anti-Cancer Agents in Medicinal Chemistry Immunogenicity of a Multiepitope Plasmid DNA Encoding T and B Lymphocyte Epitopes from Latent Membrane Protein 2 (LMP2) of Epstein-Barr Virus as a Vaccine in Mice
Protein & Peptide Letters Patent Selections:
Recent Patents on Food, Nutrition & Agriculture Patent Selections
Current Biomarkers (Discontinued) The Roles of the Unique Prolyl Isomerase Pin1 in Cancer-Related Viral and Bacterial Infections
Current Molecular Medicine Cellular Senescence as a Target in Cancer Control
Current Cancer Therapy Reviews Small Interfering RNA for Effective Cancer Therapies
Mini-Reviews in Medicinal Chemistry Synthetic Methods Applied in the Preparation of Coumarin-based Compounds
Current Organic Chemistry Gene-Nutrient Interactions in One-Carbon Metabolism
Current Drug Metabolism A Review on Important Histone Acetyltransferase (HAT) Enzymes as Targets for Cancer Therapy
Current Cancer Therapy Reviews Epidemiology, Clinical Presentation and Treatment of Mucosal Melanoma
Clinical Cancer Drugs Terpyridines and their Complexes with First Row Transition Metal Ions:Cytotoxicity, Nuclease Activity and Self-Assembly of Biomacromolecules
Current Topics in Medicinal Chemistry The Role of Parthenolide in Intracellular Signalling Processes: Review of Current Knowledge
Current Signal Transduction Therapy Drugs as Possible Triggers of Takotsubo Cardiomyopathy: A Comprehensive Literature Search - Update 2015
Current Clinical Pharmacology Multidrug Resistance ABC Transporter Structure Predictions by Homology Modeling Approaches
Current Drug Metabolism Anticancer and Antibacterial Activity of Hyperforin and Its Derivatives
Anti-Cancer Agents in Medicinal Chemistry